3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
ponatinib
4
pembrolizumab
3
Rituximab
3
Gemcitabine
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
pralsetinib
2
napabucasin
2
Vincristine
2
Prednisone
2
Irinotecan
2
Imatinib Mesylate
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
Brentuximab Vedotin
2
tetulomab tetraxetan lu-177
1
ruxolitinib
1
ricolinostat
1
pomalidomide
1
pamiparib
1
nirogacestat
1
nilotinib
1
ibritumomab tiuxetan
1
denileukin diftitox
1
bosutinib
1
blinatumomab
1
Vorinostat
1
Temozolomide
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Histologic Type
×
pertuzumab
×
Clear all
No trials found.